Skip to Content

Archives: Publication

A First-in-Human Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Neutralization Profile of Two Investigational Long-Acting Anti-SARS-CoV-2 Monoclonal Antibodies

ACE2 mimetic antibody potently neutralizes all SARS-CoV-2 variants and fully protects in XBB.1.5 challenged monkeys. Fenwick et al., 2023

SARS-CoV-2 Omicron potently neutralized by a novel antibody with unique Spike binding properties. Fenwick et al., 2022

A highly potent antibody effective against SARS-CoV-2 variants of concern. Fenwick et al., Cell 37(2), 2021.

Morbi ac felis. Sed magna purus, fermentum eu, tincidunt eu, varius ut, felis. Pellentesque libero tortor, tincidunt et, tincidunt eget, semper nec, quam. Aliquam eu nunc. Fusce vulputate eleifend sapien. Phasellus viverra nulla ut metus varius laoreet. Etiam ut purus mattis mauris sodales aliquam. In ac felis quis tortor malesuada pretium. Curabitur suscipit suscipit tellus. […]

Back to top